N
INBX icon

Nuveen’s Inhibrx INBX Stock Holding History

Nuveen’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.15M Buy
17,177
+87
+0.5% +$6.45K ﹤0.01% 2519
2025
Q4 		$1.35M Sell
17,090
-494
-3% -$33.7K ﹤0.01% 2465
2025
Q3 		$592K Sell
17,584
-3,630
-17% -$89.4K ﹤0.01% 2838
2025
Q2 		$303K Sell
21,214
-3,807
-15% -$49.2K ﹤0.01% 3052
2025
Q1 		$350K Hold
25,021
– – ﹤0.01% 3000
2024
Q4 		$385K Sell
25,021
-15,850
-39% -$241K ﹤0.01% 3070
2024
Q3 		$640K Buy
40,871
+20,166
+97% +$283K ﹤0.01% 2928
2024
Q2 		$293K Buy
+20,705
New +$323K ﹤0.01% 3156

Other funds holding INBX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Nuveen's INBX Position: Q1 2026 in Review

Nuveen increased its Inhibrx (INBX) stake by 0.51% in Q1 2026, buying an estimated $6.45K and bringing the position to 17,177 shares worth $1.15M. The position accounts for ﹤0.01% of the portfolio, ranked #2519.

Nuveen first reported a position in INBX in Q2 2024 and has held it in 8 quarters since. The position peaked at $1.35M in Q4 2025. 135 funds tracked by Wall St. Rank hold INBX as of Q1 2026.

  • Nuveen held 17,177 shares of Inhibrx worth $1.15M as of Q1 2026.
  • Nuveen bought 87 Inhibrx shares in Q1 2026, an estimated $6.45K.
  • Inhibrx made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #2519 holding.
  • Nuveen first reported a position in Inhibrx in Q2 2024 and has held it in 8 quarters since.
  • Nuveen's Inhibrx position peaked at $1.35M in Q4 2025.
  • 135 funds tracked by Wall St. Rank held Inhibrx as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.